`Zhu et al.
`
`I 111111111111111111111111111111111111 lllll 111111111111111111111111111111111
`US006432973Bl
`US 6,432,973 Bl
`Aug. 13, 2002
`
`(10) Pateut No.:
`(45) Date of Patent:
`
`(54) WATER SOLUBLE RAPAMYCIN ESTERS
`
`(75)
`
`Inventors: Tianmin Zhu, Monroe, NY (US);
`Mahdi Fawzi, Morristown, NJ (US)
`
`(73) Assignee: Wyeth, Madison, NJ (US)
`
`( *) Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`
`(21) Appl. No.: 09/954,782
`
`(22) Filed:
`
`Sep. 18, 2001
`
`Related U.S. Application Data
`(60) Provisional application No, 60/233,776, filed on Sep, 19,
`2000.
`
`(51)
`
`Int. Cl.' .................... C07D 498/16; C07D 498/18;
`C07D 491/06; A61K 31/395; A61K 31/445
`(52) U.S. Cl . ........................................ 514/291; 540/456
`(58) Field of Search ........................... 540/456; 514/291
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`3,9'29,992 A
`3,993,749 A
`4,316,885 A
`4,375,464 A
`4,401,653 A
`4,650,803 A
`4,885,171 A
`5,023,262 A
`5,023,263 A
`5,078,999 A
`5,080,899 A
`5,093,338 A
`5,093,339 A
`5,100,883 A
`5,100,899 A
`5,102,876 A
`5,118,677 A
`5,118,678 A
`5,120,842 A
`5,130,307 A
`5,151,413 A
`5,162,333 A
`5,177,203 A
`5,206,018 A
`5,221,670 A
`5,233,036 A
`5,256,790 A
`5,258,389 A
`5,260,300 A
`5,262,423 A
`5,2&5,730 A
`5,2&5,731 A
`5,288,711 A
`5,302,584 A
`5,321,009 A
`5,362,718 A
`5,385,908 A
`5,385,909 A
`
`12./1975 Sehgal et al. ............... 424/122
`11/1976 Sehgal et al. ............... 424/122
`2./1982 Rakhit ........................ 424/122
`3/1983 Sehgal et al. ............... 424/122
`8/1983 Eng ..................... , ..... 424/114
`3/1987 Stella et al.
`................ 514/291
`12./1989 Surendra et al. ............ 424/122
`6/1991 Caulfield et al.
`........... 514/291
`6/1991 Von Burg ................... 514/291
`1/1992 Warner et al. .............. 424/122
`1/1992 Strum et al. ................ 424/122
`3/1992 Byrne et al. ................ 514/291
`3/1992 Kasama et al. ............. 514/291
`3/1992 Schiehser ................... 514/183
`3/1992 Caine ......................... 514/291
`4/1992 Caulfield .................... 514/183
`6/1992 Caufield ..................... 514/183
`6/1992 Kao et al. ................... 514/183
`6/1992 Failli cl al. ................. 540/452
`* 7/1992 Failli et al. ................. 514/321
`9/1992 Caufield et al.
`.............. 514/63
`11/1992 Failli et al. ................. 514/291
`1/1993 Failli ct al. ................. 540/456
`4/1993 Sehgal et al, ............... 424/122
`* 6/1993 Caufield ..................... 514/183
`8/1993 Hughes ...................... 540/455
`10/1993 Nelson ....................... 514/291
`11/1993 Goulcl et al. ............... 514/291
`11/1993 Hu ............................. 514/291
`11/1993 Kao ........................... 514/291
`2/1994 Caufield et al.
`............ 514/291
`2/1994 Caufield et al.
`............ 514/291
`2/1994 Mitchell et al.
`.............. 514/56
`4/1994 Kao et al. ..................... 514/80
`6/1994 Bneder et al ................. 514/15
`11/1994 Skotnicki ..................... 514/63
`1/1995 Nelson et al ............... 514/291
`1/1995 Nelson et al.
`.............. 514/291
`
`5,385,910 A
`5,387,589 A
`5,389,639 A
`5,391,730 A
`5,411,967 A
`5,434,260 A
`5,463,048 A
`5,480,988 A
`5,480,989 A
`5,489,680 A
`5,491,231 A
`5,496,832 A
`5,504,091 A
`5,516,770 A
`5,516,781 A
`5,530,006 A
`5,536,729 A
`5,559,121 A
`5,561,138 A
`5,616,588 A
`5,665,772 A
`5,780,462 A
`5,985,325 A
`5,989,591 A
`
`1/1995 Ocain ct al. ...... , .... , .... 514/291
`2/1995 Kulkarni ..................... 514/291
`2/1995 Failli et al. ................. 514/291
`2/1995 Skotnicki et al. .......... , 540/456
`5/1995 Kao et al. ................... 514/291
`7/1995 Skotnicki et al. .......... , 514/291
`10/1995 Skotnicki et al. ........... 540/456
`1/1996 Failli et al. ................. 540/456
`1/1996 Kao et al. ................... 540/456
`2/1996 Failli et al. ................. 540/456
`2/1996 Nelson et al.
`.............. 540/456
`3/1996 Armstrong ................. , 514/291
`4/1996 Molnar-Kimber .......... , 514/291
`5/1996 Waranis et al .............. 514/183
`5/1996 Morris et al. ............... 514/291
`6/1996 Waranis et al. ............. 514/291
`7/1996 Waranis et al. ............. 514/291
`9/1996 Harrison et al. ............ 514/291
`10/1996 Armstrong .. , .............. , 514/291
`4/1997 Waranis el al. ............. 514/291
`9/1997 Cottcns et al. .............. 514/514
`* 7/1998 Lee et al.
`................... 514/183
`11/1999 Nagi .......................... 424/482
`11/1999 Nagi .............. ,., ........ , 424/493
`
`FOREIGN PATENT DOCUMENTS
`
`EP
`EP
`WO
`
`0 525 960 Al
`781 776
`WO 94/25072
`
`2/1993
`* 7/1997
`• 11/1994
`
`OTHER PUBLICATIONS
`
`C.V. Vezina et al., J, Anitbiol., 1975, 721,28.
`H.A. Baker et al., J. Antibiot., 1978, 539,31.
`FASEB, 1989, 3411,3.
`FASEB, 1989, 5256,3.
`R.Y. Calne et al., Lancet, 1978, 1183.
`R. Martel et al., Can. J. Physiol. Pharmacol., 1977, 48, 55.
`T. Matsumoto et al., Alheroschlerosis, 1998, 95, 139.
`S.E. Roselaar el al., J. Clio. Invest., 1995, 1906, 96.
`K.B. Lemstmm et al., Arterioscler. Thomb. Vase. Biol. 1996,
`553, 16(4).
`T. Quaschning el al., Kidney In!., 1999, S235, 56(71).
`E.E. Emeson el al., Am. J. Pathol., 1993, 1906, 142(6).
`J. Gibbons et al., Proc. Am. Assoc. Can. Res., 1999, 301, 40.
`B. Geoerger et al., Proc. Am. A<;.,;;oc. Can. Res,, 1999, 603,
`40.
`.J. Alexandre, Bull. Cancer, 1999, 808-811, 86.
`.J. Alexandre et al., Clio. Cancer Res., 1999,Abstract 7, Nov.
`Suppl.
`* cited by examiner
`Primary Examiner---Rruck Kifle
`(74) Attorney, Agent, or Firm-Arnold S. Milowsky
`ABSTRACT
`
`(57)
`
`This invention provide pegylated hydroxyesters of rapamy~
`cin which are useful in inducing immunosuppression and in
`the treatment of transplantation rejection, autoimmune
`diseases, solid tumors, fungal infections, and vascular dis(cid:173)
`ease.
`
`18 Claims, No Drawings
`
`A J'l'EXHil31T~
`De~·ll·?·l ny·. e,_ r I,· ,s
`I,· ':J'{/;/ "'
`ih l
`rf~te-~-O_Rptr,~
`,WWW.DEPOBOOK.COM
`
`Breckenridge Exhibit 1092
`Zhu '973 Patent
`Page 001
`
`
`
`US 6,432,973 Bl
`
`19
`
`5
`
`10
`
`15
`
`20
`R7 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7
`carbon atoms, alkynyl of 2-7 carbon atoms,
`---{CR'R'),OR'°, -CF,, -F, or -C02R";
`R8 and R9 are each, independently, hydrogen, alkyl of 1-6
`carbon atoms, alkenyl of2-7 carbon atoms, alkynyl of
`2-7 carbon atoms, ---(CR3R4)_f)R10
`, -CF3 , -F, or
`-C02R11
`;
`R 10 is hydrogen or -COCH2-S-CH2CH2-(0-
`CH2-CH:i),,-OCH3;
`R11 is hydrogen, alkyl of 1-6 carbon atoms, alkcnyl of
`2-7 carbon atoms, alkynyl of 2-7 carbon atoms, or
`phcnylalkyl of 7-10 carbon atoms;
`b=0-6;
`d=0-6;
`f=0-6;
`0=5--450;
`with the proviso that R1 and R2 are both not hydrogen and
`further provided that either R 1 or R2 contains at least one
`
`20 ---(CR3R'1)1OR10 group in which R10 is -COCH2......._.s(cid:173)
`Cil2Cil2---(0-Cll2-Cil2),,-0CI-I3, or a pharmaceuti~
`cally acceptable salt thereof, and a pharmaceutical carrier.
`17. A compound which is rapamycin 42-cster with
`3-h y droxy-2-(2- iodo- ace toxym e thy 1)-2-me thy 1-propioni c
`acid.
`18. A compound which is rapamycin 42-ester with 3-(2-
`Iodo-ace toxy )-2-( 2-iodo- ace to xy me thy 1 )-2-me thy 1-
`propionic acid,
`
`wherein
`R1 and R2 are each, independently, hydrogen or --CO
`(CR'R'MCR'R6)dCR'R8 R9
`;
`R3 and R'1 are each, independently, hydrogen, alkyl of 1-6
`carbon atoms, alkenyl of2-7 carbon atoms, alkynyl of 25
`2-7 carbon atoms, trifluoromethyl, or -F;
`R5 and R6 are each, independently, hydrogen, alkyl of 1-6
`carbon atoms, alkenyl of 2--7 carbon atoms, alkynyl of
`2-7 carbon atoms, -(CR3R4)pR10
`, -CF3 , -F, or
`--C02R11;
`
`* * * * *
`
`Breckenridge Exhibit 1092
`Zhu '973 Patent
`Page 0011
`
`